全球Adalimumab 市场分化,按药物类别(抗疟药物、TNF Alfa Ishibiters等)、剂量强度(40mg/0.4mg、80mg/0.8mg、20mg/0.2mg、10mg/0.1mlg等)、药物类型(红外和普通)、管理路线(管、家长等)、年龄组(儿科、成人和老年病)、剂量形式(表、注射、溶液等)、最终用户(医院/0.8mg、20mg/0.8mg/0.2mg、10mg/0.1mg等)、药物类型(红外和普通)、管理路线(管、家长等)、药物类别(儿科、成人和老年病)、剂量等级(表、注射、溶液等)、剂量强度(40mg/0.4mg/0.4mg、80mg/0.8mg、20mg/0.2mg/0.10mg/mg/mg等)、其他药物类型(医院、特殊临床治疗和医院、其他治疗、治疗、其他疾病、治疗、治疗、治疗、治疗和
市场大小
- 根据数据桥市场研究分析,全球市场规模的价值为:2025年220.9亿美元并可望达到到2033年达到33.39亿美元, 以美元计CAGR为5.3%预测期间
- 市场增长主要是由于风湿性关节炎、发作性肠道炎等自发性免疫疾病日益普遍,以及提高认识和诊断率的提高,导致对有效的生物学疗法的需求增加。
- 此外,越来越多的生物同系物被采用,治疗应用得到扩大,医疗开支增加,正在加速采用Adalimumab解决方案,从而大大地推动了该行业的增长。
市场大小和预测
全球市场价值(2025):220.9亿美元
预期市场价值(2033年):33.39亿美元
预测CAGR(2026-2033):5.30%
市场分析
- Adalimumab是一种单克隆抗体,用于治疗各种自体免疫疾病,在现代保健中越来越重要,因为它有效地管理了各种治疗领域的慢性炎症,提高了病人的生活质量。
- 对Adalimumab的需求不断上升,主要是由于自体免疫疾病发病率上升,生物学和生物同位素的采用增加,以及对早期诊断和治疗的认识提高。
- 北美主导了Adalimumab市场,2025年收入份额最大,为41.8%,其驱动力是高生物学的采用、强大的保健基础设施以及关键制药公司的存在,美国通过增加多种迹象的使用做出了重大贡献。
- 亚太区域预计将在预测期间成为增长最快的阿达利穆马布市场区域,其CAGR的增长率为13.6%,而医疗保健支出增加、生物文献的获取机会增加以及自发免疫疾病的发病率增加则使这一比率上升。
- 2025年,由于Adalimumab的生物学性质,注入部分占了市场的主导地位,收入份额为90.1%。 可注射制剂确保有效交付和迅速行动
报告范围和市场分割
|
属性 |
Adalimumab 关键市场透视 |
|
覆盖部分 |
|
|
涵盖国家 |
北美
欧洲
亚太
中东和非洲
南美洲
|
|
关键市场玩家 |
• 阿布维(美国) |
|
市场机会 |
|
|
添加数据信息集的值 |
除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。 |
市场趋势
“......日益采用生物同异性和针对性生物学疗法“
- 全球adelimumab市场的一个重要和正在加速的趋势是,越来越多地采用生物同位素和高级生物疗法,旨在改善治疗的可得性和成本效益。 随着品牌生物学专利的到期,多个类似生物版本的adalimumab已经进入市场,加强了竞争,扩大了患者在不同地区的准入范围.
- 例如,美国和欧洲等关键市场引进了类似活体瘤生物药物,大大降低了治疗费用,使更多的病人受益于慢性炎症的疗法,如风湿性关节炎、发作和克罗恩病。
- 这一趋势还反映出向个性化和有针对性的治疗方法的日益转变,由于生物学的功效更高,而且有能力解决与自体免疫障碍有关的具体免疫途径,因此越来越倾向于生物学。
- 此外,制药公司正注重改进药物交付机制,如预装注射器和自动注射器等,以提高病人的方便性,将剂量误差降到最低,并更好地遵守长期治疗办法。
- 各种自体免疫和炎症,包括口腔炎和乌韦炎的生物相似性及其类似性迹象的扩大,进一步加强了市场需求。
- 在现实世界证据和临床数据的支持下,医师对生物相似物的信心得到提高,这也加快了它们在发达和新兴市场的采用
- 此外,制药公司与保健提供者之间的战略合作正在促进更广泛的分销和提高认识,从而支持市场持续增长。
市场动态
驱动程序
“增加自动免疫疾病发病率并增加生物学治疗需求”
- 全世界自体免疫和慢性炎症发病率不断上升,是阿达利穆马布市场的一个主要驱动力。 风湿性关节炎、溃疡性结膜炎、肾上腺炎和发作等疾病日益普遍,对有效的生物学治疗提出了持续的需求。
- 例如,在2025年,一些保健系统扩大了对生物疗法的报销范围,包括类似阿达利穆马布生物疗法,大大提高了患者获得治疗和驾驶治疗的采纳率。 预计这些举措将在预测期间加速市场增长。
- 提高病人和保健提供者对自体免疫疾病早期诊断和及时治疗的认识,进一步促进了对生物记录学的需求。
- 与常规系统治疗相比,越来越倾向于提供更好的疗效、更快的症状缓解和减少副作用的定点疗法,这也有助于扩大市场。
- 保健支出增加,特别是在新兴经济体,有助于更好地获得先进疗法,并支助生物治疗基础设施的发展
- 此外,生物技术的进步,包括制剂技术的改进和药物稳定性的提高,正在加强创新生物疗法的管道。
- 专科诊所和输液中心在管理生物疗法方面发挥越来越大的作用,这也促进了不同病人群体更广泛地采用这种疗法。
- 此外,有利的政府举措和罕见疾病支助方案正在促进在长期疾病管理战略中使用生物学
限制/挑战
“......高处理成本和监管复杂性“
- 与生物疗法有关的高费用,包括治疗创伤,仍然是一项重大挑战,特别是在保健预算和报销框架有限的发展中区域。
- 例如,尽管有生物相似物,但在低收入和中等收入国家,负担能力仍然令人关切,因为自付费用可能限制患者获得长期治疗。
- 此外,对生物相似性审批的严格监管要求,包括广泛的临床试验、药典和可比性研究,可能延迟产品发射并增加制造商的开发成本。
- 生物制造工艺的复杂性,包括需要先进的生物反应器系统和严格的质量控制措施,也助长了生产成本的提高和供应链的挑战。
- 此外,与免疫力和病人在生物记录学和生物同位素之间的转换有关的问题可能影响医生的信心,并会在某些市场上缓慢地采用。
- 一些地区的病人和保健提供者对生物相似性的认识和误解有限会进一步妨碍市场渗透
- 后勤挑战,包括冷链储存和运输需求,也增加了生物分布的总体成本和复杂性
- 通过定价战略、监管协调、改进生物安全和效力教育以及扩大偿还政策来应对这些挑战,对确保市场持续增长至关重要
市场范围
市场按药物类别,说明,种类,剂量强度,药物类型,管理路线,年龄组,剂量形式,最终用户,配送渠道分出.
• 按毒品类别分列
基于药物类,Adalimumab市场被分出为Antirheumatics,TNF Alpha Inhibiters等. TNF Alpha Inhibiters分部在2025年以62.4%的收入份额支配了市场,其驱动力在于其在治疗各种自体免疫疾病方面已经证明的功效. Adalimumab作为主要的TNF抑制剂,被广泛用于慢性炎症,如风湿性关节炎和克罗恩病. 强烈的临床证据、监管批准和医生偏好助长了其支配地位。 医院和专科诊所由于其有针对性的行动和长期疾病管理的好处,严重依赖TNF抑制剂. 全球自体免疫障碍的日益普遍正在支持需求。 制药公司正在对这一类生物学的发展进行大量投资。 发达市场的优惠补偿政策进一步加强了采用。 由于结果的改善和疾病进展的减少,患者的坚持率也很高。 生物疗法的持续创新正在提高TNF抑制剂的功效. 该部分得益于强大的品牌存在和广泛的分销网络。 意识的提高和早期诊断进一步推动了部分的增长。
由于对综合关节炎管理解决方案的需求日益增加,预计2026年至2033年,抗风湿分会最快达到9.6%的CAGR. 风湿性关节炎和相关疾病的增加正在推动采用先进的抗风药物。 保健提供者正注重综合疗法,包括为病人提供更好的治疗结果。 在新兴市场扩大获得治疗的机会有助于增长。 药物制剂的技术进步正在提高功效和安全情况。 老年人口的增长是支撑需求的关键因素。 政府旨在改善关节炎护理的举措正在进一步加快收养。 提高病人的认识和获得保健服务的机会正在推动诊断率。 研发活动正在扩大抗风疗法的管道。 制药公司之间的战略合作正在增加产品供应。 与其他生物学相比,成本效益也支持采用。 预计该部分在预测期间将获得强有力的牵引力。
• 通过指示
根据说明,该市场被划分为:风湿性关节炎、Ankylosing Spondylitis、慢性血压性脊髓灰质炎、克罗恩氏病、溃疡性结肠炎、血压性关节炎、少年精神病性关节炎、Hidradenitis Suppurativa、非感染性中层尿道炎等。 风湿性关节炎部分在2025年以收入份额28.7%占市场主导地位,受该疾病全球高流行率的驱动. Adalimumab被广泛用作中度至重度风湿性关节炎的一线生物学治疗. 医院和诊所优先采取早期干预措施,防止共同损害和残疾。 提高认识和提高诊断能力有助于早期治疗。 该部分得益于支持长期效力的强有力的临床证据。 不断增加的保健支出和获得生物记录学的机会正在支持增长。 制药公司正在集中力量扩大风湿类关节炎治疗指标。 病人支助方案正在改进治疗的坚持程度。 生物同位素的提供也使治疗更容易获得。 政府管理关节炎的举措正在进一步支持需求。 治疗协议的持续进步正在提高结果。 该部门仍然是市场的主要收入提供者。
Crohn的疾病部分预计将在2026至2033年间以10.2%的CAGR最快, 对胃肠道疾病的认识日益提高,导致早期诊断和治疗。 Adalimumab因其目标机制而越来越多地被用于克罗恩病的长期管理. 生物学比常规疗法的应用日益增加,正在推动增长。 新兴市场保健基础设施的改善有助于获得保健服务。 以肠胃疾病为重点的研究活动正在扩大治疗选择。 病人越来越偏好最低程度的侵入性有效疗法,这助长了需求。 保健提供者强调个性化治疗方法。 扩大临床征兆和批准范围,正在进一步加快采用. 发达区域的支助性偿还政策正在帮助增长。 药物提供系统的技术进步正在改善病人的遵守。 该部分准备在预测期间大力扩展。
• 按类型
根据类型,市场被分化为"生物"和"生物类". 2025年,由于广泛使用有品牌的Adalimumab产品,生物部门在市场上占有主导地位,收入份额为71.3%。 生物学提供高效和有针对性的治疗,使它们成为保健提供者的首选。 品牌的强大认可和广泛的临床验证有助于它们的主导地位. 制药公司继续投资于生物创新和生命周期管理. 医院和专科诊所依靠生物记录来管理复杂的自体免疫状况。 患者高度信任和既定的治疗规程支持收养。 该部分受益于强有力的分销网络和全球存在。 发达市场的优惠补偿政策进一步加强了无障碍环境。 生物制剂的不断改进正在推动增长。 慢性病发病率的不断上升正支撑着需求。 战略伙伴关系和营销努力正在加强市场地位。 该地段仍然是adelimumab市场的支柱.
生物类似物部分预计将在2026-2033年达到13.4%的最快CAGR,其驱动力是成本效益和越来越多的监管批准. 生物类似物为品牌生物学提供了负担得起的替代品,扩大了获得治疗的机会。 各国政府和保健系统正在推广类似生物技术,以降低保健费用。 医生和病人越来越接受收养。 由于价格敏感性,新兴市场正在面临强劲的需求。 制药公司正在推出多种类似生物的版本,增加了竞争. 生物类似物的监管途径正在变得更加简化。 日益重视可负担的保健正在推动市场渗透。 技术进步正在提高生物质量和效力。 战略合作正在加强全球分布。 提高认识运动正在增强对生物类似物的信心。 预计该部分将大大地改变竞争环境。
• 最终用户
在最终用户的基础上,市场分为医院、专科诊所、家庭护理等。 2025年,在病人大量流入和提供先进治疗设施的推动下,医院部分占了市场主导地位,收入份额为48.9%。 医院是诊断、治疗和自我免疫疾病管理的主要中心。 该部分受益于熟练的保健专业人员和多学科护理办法。 获得先进的诊断工具和生物疗法有助于增长。 医院在管理可注射的生物学(如adalimumab)方面发挥着关键作用。 越来越多的住院和慢性病病例正在驱动需求。 强有力的采购制度和保险范围助长了部门支配地位。 政府供资和保健基础设施的发展进一步支持增长。 医院也参与临床试验和研究活动. 患者对医院治疗的信任度很高. 先进技术的结合可提高治疗结果。 该地段继续主导市场.
家庭护理部分预计将在2026年至2033年期间以11.1%的速度获得最快的CAGR,其动力是越来越偏爱自我管理和方便。 Adalimumab经常通过皮下注射进行,使其适合家庭使用。 患者更喜欢家庭护理来减少出院和相关费用. 对自我注射技术的认识不断提高,有助于收养。 药物运载工具的技术进步正在提高使用方便度。 这部分病人需要长期治疗。 远程保健和远程监测解决办法进一步促成家庭治疗。 政府促进家庭保健的举措正在加速增长。 老年人口的增加是驱动需求的关键因素。 成本效益和改善病人的舒适性是主要的优点。 制药公司正在集中实施病人家庭护理支助方案。 预计该部分在未来几年将大幅扩展。
• 按剂量强度
根据剂量强度,市场被分割成40mg/0.4ml,80mg/0.8ml, 20毫升/0.2毫升,10毫升/0.1毫升等. 40mg/0.4ml部分在2025年占据了市场主导地位,收入份额为52.6%,其驱动力在于它被广泛用作多种症状的标准维持剂量,如风湿性关节炎、克罗恩病和多发性病等。 医生更喜欢这种剂量,因为其临床效果得到证明,安全情况平衡。 它通常用于长期治疗,确保持续的需求。 医院和专科诊所严重依赖这种剂量进行治疗。 该部分得益于支持其使用的强有力的临床准则。 由于优化剂量频率而导致患者高度坚持,进一步促进了生长. 制药公司既注重生物学,也注重生物同位素的这种强度. 预装注射器的可用性可增进方便。 慢性病发病率的不断上升正支撑着需求。 已建立的供应链确保容易获得。 由于该部分具有多面性,因此继续领先。
80mg/0.8ml段预计将在2026至2033年达到10.7%的最快CAGR,其驱动力是越来越多地用作装载剂量和在重病条件下. 医生正在采用更高的初始剂量,以加快治疗反应。 皮肤科和胃肠道科的分泌 中度至重度自发性免疫疾病病例不断增加,有助于增长。 增加剂量的临床结果的改善正在鼓励采用。 制药公司正在推广优化剂量方法。 提高保健提供者的认识正在提高使用率。 该部分得益于药物运载工具的进步。 越来越倾向于快速症状控制是驱动需求的因素。 扩大治疗准则有助于提高剂量利用率。 新兴市场也在为增长作贡献。 预计该部分将在预测期间稳步扩大。
• 按药物类型分列
根据毒品类型,市场分为品牌和普通两种。 该品牌部分在原出自Adalimumab产品的强劲全球影响下,在2025年以64.8%的收入份额支配了市场. 这些药物得益于既定的临床疗效、品牌信任和医生偏好。 医院和专科诊所经常依靠有名的生物医学进行关键治疗. 该段得到广泛的临床试验和监管批准的支持. 病人的高度信心和一致的治疗结果助长了支配地位。 制药公司对品牌药品的营销和生命周期管理投入了大量资金. 发达区域的优惠偿还政策进一步支持增长。 该部分还受益于全球分销网络。 自我免疫疾病的日益流行正在推动需求。 强有力的专利保护历来支持市场领导。 即使是专利期满后,品牌忠诚依然坚定. 这一部分继续占有很大份额。
由于越来越重视成本效益高的治疗方案,通用软件部分预计将在2026年至2033年达到12.9%的最快CAGR。 保健费用的上升正在鼓励采用非专利替代品。 各国政府和管理机构正在推广通用技术,以改善无障碍环境。 由于承受得起,新兴市场的需求强劲。 制造商之间日益激烈的竞争正在推动价格的降低。 医生逐渐接受通类药物进行长期治疗. 扩大监管审批支持入市. 技术进步正在提高仿制药质量。 患者对负担得起的治疗的认识正在提高。 战略合作正在加强分配。 该部分还得到政府优惠政策的支持。 预计通用产品在未来几年将显著地扩大其市场存在。
• 按行政路线
根据管理路线,市场分为口述、家长等。 2025年,由于adalimumab是一种通过皮下注射管理的生物,其收入份额为88.3%。 家长管理确保了生物利用率高和迅速的治疗行动。 医院和家庭护理设施广泛采用这一途径,以有效管理疾病。 该分会得益于既定的临床规程. 预先填充的注射器和自动注射器提高了使用方便度. 越来越多的自我注射正在支持增长。 制药公司注重改进注射装置。 由于方便用药,病人遵守要求很高。 这一部分对于管理慢性自体免疫状况至关重要。 技术进步正在改善病人的经验。 强有力的临床证据支持了这条路线. 该部门因其有效性而仍然占主导地位。
口服部分预计将在2026年至2033年期间最快达到8.7%的CAGR,这是目前对替代分娩方法的研究所推动的。 目前口服生物学虽然有限,但正得到人们的注意,以改善病人的方便。 制药公司正在投资于创新的药物提供技术。 患者更喜欢非侵入性治疗方法,支持未来需求. 配方科学的进步促进了口腔生物学的发展. 越来越注重以病人为中心的护理正在推动研究。 随着新产品获得核准,预计该部分将会增加。 改善遵约和减少不适是关键优势。 新兴技术正在克服生物利用方面的挑战。 研发投资增长加快推进. 这一部分具有长期增长潜力。 预计在预测期间,收养将逐步增加。
• 按年龄组分列
根据年龄组,市场分为小儿科、成人科和老年科。 2025年,成人部分的收入份额为58.2%,这是成年人自发免疫疾病高发所驱动的。 成人是多种症状下的主要治疗对象。 与生活方式有关的疾病不断增加,导致疾病的发生。 医院和诊所主要关注成人病人护理。 该部分得益于高诊断率和治疗方便。 制药公司针对这一群体采用量身定制的疗法。 提高保健意识有助于早期治疗。 成人病人更容易获得保险。 该部分得到了广泛的临床研究的支持. 与工作有关的压力和环境因素不断增加,加重了疾病负担。 持续监测和长期治疗驱动需求。 该部门仍然是最大的捐助者。
2026至2033年,由于全球人口迅速老化,老年部分预计将达到10.3%的最快CAGR。 老年人更容易患上慢性炎症。 预期寿命的延长正在促使治疗需求增加。 保健提供者正集中力量为老年病人提供专门护理。 生物疗法的进展正在改善老年病的安全情况。 家庭护理收养的比例较高。 政府保健方案支持老年人治疗。 提高对疾病管理的认识正在推动增长。 改善获得保健服务的机会正在作出贡献。 技术进步正在加强病人监测。 由于医疗需求得不到满足,这部分人正受到关注。 预计在预测期间增长仍将强劲。
• 剂量表
根据剂量形式,市场被分割成平板,注射,溶液等. 2025年,由于Adalimumab的生物学性质,注入部分占了市场的主导地位,收入份额为90.1%。 可注射制剂确保有效交付和迅速行动。 医院和家庭护理设施广泛使用预填注射器和自动注射器。 该分会得益于强大的临床验证. 越来越多的自我注射装置的采用正在支持增长。 制药公司注重改进注射技术. 患者因方便而高度坚持是关键因素. 这一部分对慢性病管理至关重要。 监管审批支持广泛使用. 先进的包装解决方案提高了可用性。 保健提供者的强劲需求推动了增长。 由于必要性,这一部分仍然占主导地位。
2026年至2033年,由于配方技术的进步,预计溶液部分将最快达到9.1%的CAGR. 解决办法使行政管理更加稳定和容易。 制药公司正在集中力量研制现成的制剂。 对方便用户的提供药物的需求日益增加,这正在支持增长。 该部分受益于生物制剂的创新. 改进储存期和储存条件可加强收养。 保健提供者更喜欢精确剂量的解决办法。 越来越注重病人的方便性正在驱动需求。 技术进步正在提高配方质量。 研究活动正在扩大产品供应。 这段路段正在逐渐增强 预计随着时间的推移,增长将加快。
• 按分发渠道
以发售渠道为基础,将市场分入医院药房,零售药房,在线药房等. 2025年,医院药房部分占了市场主导地位,收入份额为54.3%,由病人大量流入和医院环境中的直接药物管理所驱动。 医院是生物学治疗初级中心。 该部分得益于强有力的采购系统和大宗采购。 保健专业人员确保妥善处理和管理。 保险范围往往与医院药房有关。 增加入院人数支持需求。 该部分得到了政府保健方案的支持。 先进的储存和装卸设施确保了药物质量。 医院在慢性病管理中发挥着关键作用. 强有力的供应链网络支持供应。 由于可靠性,该段继续领先.
在线药房部分预计将在2026年至2033年实现13.2%的CAGR最快,其动力是越来越多的数字化和电子商务在医疗保健领域的采用。 患者更喜欢在线平台提供方便和家庭分娩. 互联网普及率的不断提高有助于扩大市场。 制药公司与在线平台建立伙伴关系。 该部分受益于竞争性定价和折扣。 越来越多的远程保健正在推动需求。 对电子药品的管理支持正在改善获取途径。 家庭护理病人严重依赖在线分发。 技术进步确保了安全交易。 对数字保健的认识的提高正在推动增长。 该部门正在新兴市场迅速扩展。 预期它在今后的分配中将起重要作用。
市场区域分析
- 2025年,在生物疗法的高入行、强大的保健基础设施以及主要制药公司的存在的推动下,北美占了市场主导地位,收入份额最大,为41.8%。 该区域受益于既定的偿还框架、对自体免疫疾病的广泛认识以及多种症状的先进生物学治疗
- 本区域的保健提供者和病人十分重视通过有针对性的疗法进行有效的疾病管理,这促进了对创伤及其生物相似性的持续需求。 提供先进的诊断设施,增加临床研究活动,建立强有力的分销网络,进一步支持市场增长.
- 该区域的高保健支出,再加上生物学和生物类似发展的不断创新,继续强化了北美在全球市场上的领先地位。
美国阿达利穆马布市场透视
2025年,美国adalimumab市场获得了北美最大的收入份额,由于在广泛的自体免疫条件下广泛使用生物疗法而火上浇油。 大型制药公司的存在、正在进行的临床试验以及有利的偿还政策大大地促进了市场的扩大。 此外,病人认识的提高、早期诊断率和生物同位素的日益采用正在推动治疗的普及。 扩大专科药店和输液中心,进一步加强了全国各地采用adalimumab疗法。
欧洲市场观察
在预测期间,由于政府对生物类似物的有力支持、建立完善的保健系统以及日益注重成本效益高的治疗办法,欧洲的阿达利穆马布市场预计将在大规模CAGR扩展。 该区域广泛采用了类似生物的阿达利穆马布产品,改善了病人的就诊情况并降低了总体治疗费用。 人们对自发性免疫疾病的认识日益提高,加上对保健基础设施和临床研究的投资不断增加,进一步促进了市场的增长。
英国阿达利穆马布市场透视
英国的Adalimumab市场预计将在值得注意的CAGR增长,而自体免疫障碍的流行率正在上升,通过国家保健方案越来越多地采用生物同物。 政府主导的降低保健成本和促进使用生物同质物的举措已大大加快了市场渗透。 此外,先进的保健设施和强有力的病人支助方案的存在提高了治疗的可获得性和坚持性。
德国 Adalimumab 市场透视
在强有力的保健系统、对生物疗法的高度认识以及对研究和创新的大力强调的推动下,德国的Adalimumab市场预计将在相当大的CAGR扩展。 德国是欧洲最大的生物同类产品市场之一,得到优惠的偿还政策和医生接受的支持。 对定向疗法的需求不断增加,主要制药厂商也越来越多,这有利于市场持续增长。
亚太市场观察
在预测期间,亚太的Adalimumab市场将以13.6%的CAGR最快的速度增长,这得益于医疗保健支出的上升、生物学的改善以及自体免疫疾病的日益流行。 快速城市化、中产阶级人口的扩大以及中国、日本和印度等国医疗保健基础设施的持续改善正在推动市场扩张。 此外,人们日益认识到对自体免疫疾病的早期诊断和治疗,以及政府为改善获得先进疗法的机会而采取的更多举措,正在进一步加快该区域的市场增长。
日本市场透视
由于先进的保健基础设施、高水平采用创新疗法以及对生物记录学和生物类似物的强有力的监管支持,日本的adalimumab市场正在获得势头。 该国人口老化和慢性炎症的日益流行,在很大程度上助长了需求。 此外,临床研究的持续进步和成熟的制药公司的存在支持了市场的稳步增长。
中国市场透视
中国市场在2025年占亚太地区最大的市场收入份额,原因是该国病人众多,医疗开支增加,医疗基础设施迅速扩大。 越来越多的具有成本效益的生物类同物可供使用,加上政府促进获得生物疗法的支持性政策,正在推动市场增长。 此外,对自发免疫疾病的认识得到提高,诊断能力得到提高,这进一步加强了城市和农村地区的收养。
市场份额
雅达利穆马布工业主要由历史悠久的公司领导,包括:
• 阿布维(美国)
二. 支助阿姆根 (美国).
• 辉瑞 (美国)
• 三星·比奥佩斯(韩国)
• 桑多斯(瑞士)
• Boehringer Ingelheim(德国)
• 弗雷塞尼乌斯·卡比(德国)
二. 支助米兰 (美国).
• 生物生物(印度)
• Zydus生命科学(印度)
• 种子药品(印度)
二. 支助阿尔沃特克(冰岛)
• Coherus生物科学(美国)
• 手机(韩国)
• Momenta制药(美国)
• 希克马制药公司(联合王国)
• Aurobindo Pharma(印度)
二. 支助鲁平(印度)
• 泰瓦制药业(以色列)
• 依赖生命科学(印度)
全球市场的最新动态
- 2021年12月,美国FDA批准了与Humira类似生物的adalimumab-aqvh(Yusimry),扩大了经批准的治疗风湿性关节炎和克罗恩病等炎症的替代品库. 这一批准标志着朝着加强竞争和改善患者获得生物疗法的关键步骤
- 2021年2月,Celltrion Healthcare因其高浓度,无柠檬酸的adalimumab生物同物(后被命名为"Yuflyma")而获得了欧洲营销授权,旨在提升患者的舒适度和剂量方便. 这一发展反映了生物同型制剂方面不断增长的创新
- 2023年1月,阿姆根在Humira专利到期后在美国推出Amjevita (adalimumab biosilar),标志着美国首次生物相仿入场并开始在adalimumab市场进行大规模竞争.
- 2023年7月,Humira失去市场独家经营权后,在美国推出了多种类似生物(包括Hyrimoz、Hadlima和Cyltezo),显著地增加了竞争,推动了生物学部分的降价。
- 2024年5月,Celltrion USA宣布以比Humira低得多的价格提供其高浓度,无柠檬酸的等效活性生物,凸显出旨在增加可负担性和加速生物同化的激进定价策略.
- 2024年5月,Boehringer Ingelheim获得美国FDA批准高浓度无柑橘配方Cyltezo (adalimumab-adbm),增强治疗便利,并适应不断演变的患者和提供商对改进生物学送药系统的偏好.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ADALIMUMAB MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 INDICATION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PIPELINE ANALYSIS
4 REGULATORY FRAMEWORK OF GLOBAL ADALIMUMAB MARKET
5 EPIDEMIOLOGY
6 ADALIMUMAB PRESCRIPTION
7 GLOBAL ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO
7.1 REIMBURSEMENT SCENARIO IN THE U.S.
7.2 REIMBURSEMENT SCENARIO IN CHINA
7.3 REIMBURSEMENT SCENARIO IN JAPAN
7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE
7.5 REIMBURSEMENT SCENARIO IN DENMARK
7.6 REIMBURSEMENT SCENARIO IN IRELAND
8 IMPACT OF BIOSIMILAR
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS
9.1.2 INCREASING GERIATRIC POPULATION
9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS
9.1.4 INTRODUCTION TO BIOSIMILARS
9.1.5 EXPLORATION OF EMERGING MARKETS
9.2 RESTRAINTS
9.2.1 HIGH COSTS OF DRUGS
9.2.2 SIDE EFFECTS OF DRUGS
9.2.3 CANCER CAUSING DRUGS
9.3 OPPORTUNITIES
9.3.1 PRESENCE OF PRODUCT PIPELINE
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 INCREASING HEALTHCARE EXPENDITURE
9.3.4 PRESENCE OF REIMBURSEMENT POLICIES
9.4 CHALLENGES
9.4.1 LOSS OF PATENTS
9.4.2 AVAILABILITY OF ALTERNATIVES
9.4.3 LONG APPROVAL PROCEDURE
10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY
10.1 OVERVIEW
10.2 ADALIMUMAB AND COVID-19
10.3 PRICE IMPACT OF COVID-19
10.4 IMPACT ON DEMAND
10.5 IMPACT ON SUPPLY CHAIN
10.6 STRATEGIC DECISIONS FOR MANUFACTURERS
10.7 CONCLUSION
11 GLOBAL ADALIMUMAB MARKET, BY INDICATION
11.1 OVERVIEW
11.2 RHEUMATOID ARTHRITIS
11.3 ANKYLOSING SPONDYLITIS
11.4 CHRONIC PLAQUE PSORIASIS
11.5 CROHN’S DISEASE
11.6 ULCERATIVE COLITIS
11.7 PSORIATIC ARTHRITIS
11.8 JUVENILE IDIOPATHIC ARTHRITIS
11.9 HIDRADENITIS SUPPURATIVA
11.1 NON-INFECTIOUS INTERMEDIATE
11.11 OTHERS
12 GLOBAL ADALIMUMAB MARKET, BY TYPE
12.1 OVERVIEW
12.2 BIOLOGICS
12.3 BIOSIMILARS
12.3.1 ADALIMUMAB-ATTO
12.3.2 ADALIMUMAB-BWWD
12.3.3 ADALIMUMAB-ADBM
12.3.4 ADALIMUMAB-ADAZ
12.3.5 ADALIMUMAB-FKJP
12.3.6 ADALIMUMAB-AFZB
12.3.7 OTHERS
13 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGTH
13.1 OVERVIEW
13.2 40MG/0.4ML
13.3 80MG/0.8ML
13.4 20MG/0.4ML
13.5 10MG/0.1ML
13.6 OTHERS
14 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 BRANDED
14.3 GENERICS
14.3.1 AMJEVITA
14.3.2 HYRIMOZ
14.3.3 HULIO
14.3.4 OTHERS
15 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 PARENTERAL
15.3 ORAL
16 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE
16.1 OVERVIEW
16.2 ADULTS
16.3 CHILDREN
17 GLOBAL ADALIMUMAB MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACIES
18.3 RETAIL PHARMACIES
18.4 ONLINE PHARMACIES
18.5 DIRECT TENDER
18.6 OTHERS
19 GLOBAL ADALIMUMAB MARKET, BY GEOGRAPHY
19.1 OVERVIEW
19.2 NORTH AMERICA
19.2.1 U.S.
19.2.2 CANADA
19.2.3 MEXICO
19.3 EUROPE
19.3.1 GERMANY
19.3.2 U.K
19.3.3 ITALY
19.3.4 FRANCE
19.3.5 SPAIN
19.3.6 NETHERLANDS
19.3.7 RUSSIA
19.3.8 SWITZERLAND
19.3.9 BELGIUM
19.3.10 TURKEY
19.3.11 AUSTRIA
19.3.12 NORWAY
19.3.13 HUNGARY
19.3.14 LITHUANIA
19.3.15 IRELAND
19.3.16 POLAND
19.3.17 REST OF EUROPE
19.4 ASIA- PACIFIC
19.4.1 JAPAN
19.4.2 CHINA
19.4.3 SOUTH KOREA
19.4.4 AUSTRALIA
19.4.5 INDIA
19.4.6 SINGAPORE
19.4.7 MALAYSIA
19.4.8 THAILAND
19.4.9 INDONESIA
19.4.10 PHILIPPINES
19.4.11 VIETNAM
19.4.12 REST OF ASIA-PACIFIC
19.5 SOUTH AMERICA
19.5.1 BRAZIL
19.5.2 ARGENTINA
19.5.3 PERU
19.5.4 REST OF SOUTH AMERICA
19.6 MIDDLE EAST & AFRICA
19.6.1 SAUDI ARABIA
19.6.2 SOUTH AFRICA
19.6.3 UAE
19.6.4 ISRAEL
19.6.5 KUWAIT
19.6.6 EGYPT
19.6.7 REST OF MIDDLE EAST & AFRICA
20 GLOBAL ADALIMUMAB MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: GLOBAL
20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
20.3 COMPANY SHARE ANALYSIS: EUROPE
20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21 SWOT
22 COMPANY PROFILES
22.1 ABBVIE INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 BIOGEN
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 PRODUCT PORTFOLIO
22.3.4 RECENT DEVELOPMENTS
22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)}
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 PRODUCT PORTFOLIO
22.4.4 RECENT DEVELOPMENTS
22.5 MYLAN N.V.
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 CELLTRION INC.
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 COHERUS BIOSCIENCES
22.8.1 COMPANY SNAPSHOT
22.8.2 PRODUCT PORTFOLIO
22.8.3 RECENT DEVELOPMENTS
22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)
22.9.1 COMPANY SNAPSHOT
22.9.2 REVENUE ANALYSIS
22.9.3 PRODUCT PORTFOLIO
22.9.4 RECENT DEVELOPMENTS
22.1 HETERO BIOPHARMA LTD.
22.10.1 COMPANY SNAPSHOT
22.10.2 PRODUCT PORTFOLIO
22.10.3 RECENT DEVELOPMENTS
22.11 INNOVENT BIOLOGICS, INC.
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 PFIZER INC.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 ZYDUS CADILA
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENT
23 QUESTIONNAIRE
24 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 GLOBAL ADALIMUMAB MARKET, PIPELINE ANALYSIS
TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.
TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)
TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS
TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT
TABLE 6 GLOBAL ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)
TABLE 7 GLOBAL RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 8 GLOBAL ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 9 GLOBAL CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 10 GLOBAL CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 11 GLOBAL ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 12 GLOBAL PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 13 GLOBAL JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 14 GLOBAL HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 15 GLOBAL NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 16 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 17 GLOBAL ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 18 GLOBAL BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 19 GLOBAL BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 20 GLOBAL BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 21 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)
TABLE 22 GLOBAL 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 23 GLOBAL 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 24 GLOBAL 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 25 GLOBAL 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 26 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 27 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 28 GLOBAL BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 29 GLOBAL GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 GLOBAL GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 31 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)
TABLE 32 GLOBAL PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 33 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)
TABLE 34 GLOBAL ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 35 GLOBAL CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 36 GLOBAL ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)
TABLE 37 GLOBAL HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 38 GLOBAL SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 39 GLOBAL HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 40 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 41 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 42 GLOBAL HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 43 GLOBAL RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 44 GLOBAL ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 45 GLOBAL DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 46 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 47 GLOBAL ADALIMUMAB MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 48 NORTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 49 NORTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 50 NORTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 51 NORTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 52 NORTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 53 NORTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 54 NORTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 55 NORTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 56 NORTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 57 NORTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 58 NORTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 59 U.S. ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 60 U.S. ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 61 U.S. BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 62 U.S. ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 63 U.S. ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 64 U.S. GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 65 U.S. ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 66 U.S. ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 67 U.S. ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 68 U.S. ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 69 CANADA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 70 CANADA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 CANADA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 72 CANADA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 73 CANADA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 74 CANADA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 75 CANADA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 76 CANADA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 77 CANADA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 78 CANADA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 79 MEXICO ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 80 MEXICO ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 81 MEXICO BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 82 MEXICO ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 83 MEXICO ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 84 MEXICO GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 85 MEXICO ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 86 MEXICO ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 87 MEXICO ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 88 MEXICO ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 89 EUROPE ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 90 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 91 EUROPE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 92 EUROPE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 93 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 94 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 95 EUROPE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 96 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 97 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 98 EUROPE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 99 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 100 GERMANYADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 101 GERMANYADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 102 GERMANYBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 103 GERMANYADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 104 GERMANYADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 105 GERMANY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 106 GERMANYADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 107 GERMANYADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 108 GERMANYADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 109 GERMANYADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 110 U.K ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 111 U.K ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 112 U.K BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 113 U.K ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 114 U.K ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 115 U.K GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 116 U.K ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 117 U.K ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 118 U.K ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 119 U.K ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 120 ITALY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 121 ITALY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 122 ITALY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 123 ITALY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 124 ITALY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 125 ITALY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 126 ITALY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 127 ITALY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 128 ITALY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 129 ITALY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 130 FRANCE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 131 FRANCE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 132 FRANCE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 133 FRANCE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 134 FRANCE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 135 FRANCE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 136 FRANCE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 137 FRANCE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 138 FRANCE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 139 FRANCE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 140 SPAIN ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 141 SPAIN ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 142 SPAIN BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 143 SPAIN ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 144 SPAIN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 145 SPAIN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 146 SPAIN ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 147 SPAIN ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 148 SPAIN ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 149 SPAIN ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 150 NETHERLANDS ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 151 NETHERLANDS ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152 NETHERLANDS BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 153 NETHERLANDS ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 154 NETHERLANDS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 155 NETHERLANDS GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 156 NETHERLANDS ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 157 NETHERLANDS ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 158 NETHERLANDS ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 159 NETHERLANDS ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 160 RUSSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 161 RUSSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 162 RUSSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 163 RUSSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 164 RUSSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 165 RUSSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 166 RUSSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 167 RUSSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 168 RUSSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 169 RUSSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 170 SWITZERLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 171 SWITZERLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172 SWITZERLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 173 SWITZERLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 174 SWITZERLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 175 SWITZERLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 176 SWITZERLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 177 SWITZERLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 178 SWITZERLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 179 SWITZERLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 180 BELGIUM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 181 BELGIUM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 BELGIUM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 183 BELGIUM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 184 BELGIUM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 185 BELGIUM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 186 BELGIUM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 187 BELGIUM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 188 BELGIUM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 189 BELGIUM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 190 TURKEY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 191 TURKEY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 192 TURKEY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 193 TURKEY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 194 TURKEY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 195 TURKEY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 196 TURKEY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 197 TURKEY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 198 TURKEY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 199 TURKEY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 200 AUSTRIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 201 AUSTRIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 202 AUSTRIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 203 AUSTRIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 204 AUSTRIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 205 AUSTRIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 206 AUSTRIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 207 AUSTRIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 208 AUSTRIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 209 AUSTRIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 210 NORWAY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 211 NORWAY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 212 NORWAY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 213 NORWAY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 214 NORWAY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 215 NORWAY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 216 NORWAY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 217 NORWAY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 218 NORWAY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 219 NORWAY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 220 HUNGARY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 221 HUNGARY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 222 HUNGARY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 HUNGARY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 224 HUNGARY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 225 HUNGARY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 226 HUNGARY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 227 HUNGARY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 228 HUNGARY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 229 HUNGARY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 230 LITHUANIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 231 LITHUANIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 232 LITHUANIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 233 LITHUANIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 234 LITHUANIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 235 LITHUANIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 236 LITHUANIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 237 LITHUANIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 238 LITHUANIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 239 LITHUANIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 240 IRELAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 241 IRELAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 242 IRELAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 243 IRELAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 244 IRELAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 245 IRELAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 246 IRELAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 247 IRELAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 248 IRELAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 249 IRELAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 250 POLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 251 POLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 252 POLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 253 POLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 254 POLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 255 POLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 256 POLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 257 POLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 258 POLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 259 POLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 260 REST OF EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 261 ASIA- PACIFIC ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 262 ASIA- PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 263 ASIA- PACIFIC ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 264 ASIA- PACIFIC BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 265 ASIA- PACIFIC ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 266 ASIA- PACIFIC ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 267 ASIA- PACIFIC GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 268 ASIA- PACIFIC ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 269 ASIA- PACIFIC ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 270 ASIA- PACIFIC ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 271 ASIA- PACIFIC ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 272 JAPANADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 273 JAPANADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 274 JAPANBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 275 JAPANADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 276 JAPANADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 277 JAPAN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 278 JAPANADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 279 JAPANADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 280 JAPANADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 281 JAPANADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 282 CHINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 283 CHINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 284 CHINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 285 CHINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 286 CHINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 287 CHINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 288 CHINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 289 CHINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 290 CHINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 291 CHINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 292 SOUTH KOREA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 293 SOUTH KOREA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 294 SOUTH KOREA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 295 SOUTH KOREA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 296 SOUTH KOREA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 297 SOUTH KOREA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 298 SOUTH KOREA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 299 SOUTH KOREA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 300 SOUTH KOREA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 301 SOUTH KOREA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 302 AUSTRALIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 303 AUSTRALIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 304 AUSTRALIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 305 AUSTRALIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 306 AUSTRALIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 307 AUSTRALIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 308 AUSTRALIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 309 AUSTRALIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 310 AUSTRALIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 311 AUSTRALIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 312 INDIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 313 INDIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 314 INDIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 315 INDIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 316 INDIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 317 INDIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 318 INDIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 319 INDIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 320 INDIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 321 INDIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 322 SINGAPORE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 323 SINGAPORE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 324 SINGAPORE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 325 SINGAPORE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 326 SINGAPORE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 327 SINGAPORE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 328 SINGAPORE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 329 SINGAPORE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 330 SINGAPORE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 331 SINGAPORE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 332 MALAYSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 333 MALAYSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 334 MALAYSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 MALAYSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 336 MALAYSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 337 MALAYSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 338 MALAYSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 339 MALAYSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 340 MALAYSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 341 MALAYSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 342 THAILAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 343 THAILAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 344 THAILAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 345 THAILAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 346 THAILAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 347 THAILAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 348 THAILAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 349 THAILAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 350 THAILAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 351 THAILAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 352 INDONESIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 353 INDONESIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 354 INDONESIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 355 INDONESIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 356 INDONESIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 357 INDONESIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 358 INDONESIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 359 INDONESIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 360 INDONESIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 361 INDONESIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 362 PHILIPPINES ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 363 PHILIPPINES ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 364 PHILIPPINES BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 365 PHILIPPINES ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 366 PHILIPPINES ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 367 PHILIPPINES GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 368 PHILIPPINES ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 369 PHILIPPINES ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 370 PHILIPPINES ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 371 PHILIPPINES ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 372 VIETNAM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 373 VIETNAM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 374 VIETNAM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 375 VIETNAM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 376 VIETNAM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 377 VIETNAM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 378 VIETNAM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 379 VIETNAM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 380 VIETNAM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 381 VIETNAM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 382 REST OF ASIA-PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 383 SOUTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 384 SOUTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 385 SOUTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 386 SOUTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 387 SOUTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 388 SOUTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 389 SOUTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 390 SOUTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 391 SOUTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 392 SOUTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 393 SOUTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 394 BRAZILADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 395 BRAZILADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 396 BRAZILBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 397 BRAZILADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 398 BRAZILADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 399 BRAZIL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 400 BRAZILADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 401 BRAZILADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 402 BRAZILADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 403 BRAZILADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 404 ARGENTINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 405 ARGENTINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 406 ARGENTINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 407 ARGENTINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 408 ARGENTINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 409 ARGENTINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 410 ARGENTINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 411 ARGENTINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 412 ARGENTINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 413 ARGENTINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 414 PERU ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 415 PERU ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 416 PERU BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 417 PERU ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 418 PERU ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 419 PERU GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 420 PERU ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 421 PERU ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 422 PERU ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 423 PERU ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 424 REST OF SOUTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 425 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 426 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 427 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 428 MIDDLE EAST & AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 429 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 430 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 431 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 432 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 433 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 434 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 435 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 436 SAUDI ARABIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 437 SAUDI ARABIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 438 SAUDI ARABIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 439 SAUDI ARABIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 440 SAUDI ARABIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 441 SAUDI ARABIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 442 SAUDI ARABIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 443 SAUDI ARABIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 444 SAUDI ARABIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 445 SAUDI ARABIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 446 SOUTH AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 447 SOUTH AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 448 SOUTH AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 449 SOUTH AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 450 SOUTH AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 451 SOUTH AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 452 SOUTH AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 453 SOUTH AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 454 SOUTH AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 455 SOUTH AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 456 UAE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 457 UAE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 458 UAE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 459 UAE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 460 UAE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 461 UAE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 462 UAE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 463 UAE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 464 UAE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 465 UAE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 466 ISRAEL ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 467 ISRAEL ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 468 ISRAEL BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 469 ISRAEL ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 470 ISRAEL ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 471 ISRAEL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 472 ISRAEL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 473 ISRAEL ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 474 ISRAEL ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 475 ISRAEL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 476 KUWAIT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 477 KUWAIT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 478 KUWAITBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 479 KUWAIT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 480 KUWAIT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 481 KUWAIT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 482 KUWAIT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 483 KUWAIT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 484 KUWAIT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 485 KUWAIT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 486 EGYPT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 487 EGYPT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 488 EGYPT BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 489 EGYPT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 490 EGYPT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 491 EGYPT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 492 EGYPT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 493 EGYPT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 494 EGYPT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 495 EGYPT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 496 REST OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
图片列表
LIST OF FIGURES
FIGURE 1 GLOBAL ADALIMUMAB MARKET: SEGMENTATION
FIGURE 2 GLOBAL ADALIMUMAB MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL ADALIMUMAB MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL ADALIMUMAB MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL ADALIMUMAB MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL ADALIMUMAB MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL ADALIMUMAB MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE HIGHEST GROWING REGION IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 13 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ADALIMUMAB MARKET IN 2020 & 2027
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL ADALIMUMAB MARKET
FIGURE 16 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 17 FUNCTION OF CRO
FIGURE 18 HEALTHCARE EXPENDITURE IN 2016 AND 2019
FIGURE 19 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019
FIGURE 20 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION)
FIGURE 21 GLOBAL ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027)
FIGURE 22 GLOBAL ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 23 GLOBAL ADALIMUMAB MARKET: BY TYPE, 2019
FIGURE 24 GLOBAL ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION)
FIGURE 25 GLOBAL ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 26 GLOBAL ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019
FIGURE 28 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION)
FIGURE 29 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027)
FIGURE 30 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE
FIGURE 31 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, 2019
FIGURE 32 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION)
FIGURE 33 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 34 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 35 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 36 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 37 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 38 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 39 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019
FIGURE 40 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION)
FIGURE 41 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027)
FIGURE 42 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019
FIGURE 44 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 45 GLOBAL ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027)
FIGURE 46 GLOBAL ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 48 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 49 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 50 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 GLOBAL ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 52 GLOBAL ADALIMUMAB MARKET: BY REGION (2019)
FIGURE 53 GLOBAL ADALIMUMAB MARKET: BY REGION (2020 & 2027)
FIGURE 54 GLOBAL ADALIMUMAB MARKET: BY REGION (2019 & 2027)
FIGURE 55 GLOBAL ADALIMUMAB MARKET: BY INDICATION (2020-2027)
FIGURE 56 NORTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 57 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 58 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 59 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 60 NORTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 61 EUROPE ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 62 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 63 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 64 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 65 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 66 ASIA- PACIFIC ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 67 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 68 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 69 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 70 ASIA- PACIFIC ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 71 SOUTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 72 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 73 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 74 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 75 SOUTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 76 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 77 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 78 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 79 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 80 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 81 GLOBAL ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
FIGURE 82 NORTH AMERICA ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
FIGURE 83 EUROPE ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
FIGURE 84 ASIA-PACIFIC ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
